Hypervision Surgical, a London-based venture building an advanced surgical imaging and data analytics platform, announced the successful completion of an oversubscribed seed funding round, raising £6.5 million. By harnessing AI and clinical edge computing, the King’s College London spin-out aims to revolutionise surgical outcomes and alleviate the global burden of surgical complications across diverse surgical specialties.
Hypervision Surgical’s Hyperspectral Intelligence platform leverages ultra-fast snapshot hyperspectral imaging and data analytics for better decision-making during surgery. It was first presented at the annual NVIDIA GTC 2022 keynote of CEO Jensen Huang as part of the “I am a visionary” section.
We are incredibly excited about the transformative potential of our Hyperspectral Intelligence platform. Imagine a complex tumour surgery where surgeons can rely on precise measurements and tissue property information to distinguish between healthy and unhealthy tissue. Our technology makes the invisible visible, empowering surgeons to make confident decisions with enhanced precision and ultimately improving patient outcomes.
— Michael Ebner, CEO and co-founder of Hypervision Surgical
The funding round was led by a syndicate of highly experienced European and American HealthTech investors, including HERAN Partners, Redalpine, LifeX Ventures, and ZEISS Ventures, the corporate venture arm of the ZEISS Group – a global technology leader operating in the fields of optics and optoelectronics.
Unleashing the power of standard surgical components: Hypervision Surgical’s vision technology reveals hidden tissue analytics insights with conventional laparoscopic components for real-time surgical guidance during an in-vivo colorectal study at IHU Strasbourg, France.
Advancing surgical vision: Hypervision Surgical’s real-time tissue analytics platform reveals dynamic tissue perfusion imaging invisible to the human eye alongside conventional red/green/blue vision during colorectal surgery.
Raf Roelands, Investment Director at HERAN Partners, stated, “Hypervision Surgical’s hardware-agnostic solution has the potential to redefine the standard of care in surgical imaging across various procedures, from open to minimally invasive, robotics, and microscopic surgeries.”
Daniel Dillinger, Investment Manager at Redalpine, emphasised, “Hypervision Surgical’s objective tissue characterisation and analytics platform is uniquely positioned to drive surgical decision-making and address critical unmet needs in the growing field of minimally invasive surgery, which sees nearly 200 million procedures annually.”
Iñaki Berenguer, Founding Partner at LifeX Ventures, highlighted the potential impact, stating, “The innovation in AI-powered vision systems, with simplified deployment in hospitals, holds the key to significantly improving the lives of millions of patients undergoing critical surgeries. Hypervision Surgical has the necessary ingredients to lead in this category.”
In conjunction with the funding announcement, Hypervision Surgical is delighted to welcome Martin Frost CBE, Founder and former CEO of CMR Surgical, to its board of directors. Frost has an extensive track record as a technology executive and director, having spent decades building and leading multiple companies, including through initial public offerings. Notably, he founded CMR Surgical in 2014 and swiftly scaled it into a globally recognised unicorn in the field of surgical robotics. In recognition of his exceptional contributions to Robotics and the British Industry, Frost was awarded a CBE in the 2020 Queen’s Birthday Honours.
We are thrilled to have Martin Frost join our board of directors. His unparalleled expertise in building and scaling surgical technology ventures will be invaluable as we navigate the next phase of Hypervision Surgical’s growth and commercialisation efforts.
— Michael Ebner, CEO and co-founder of Hypervision Surgical
The newly secured funding will accelerate the development of Hypervision Surgical’s cutting-edge vision technology and be used to attain regulatory clearance in the United States and Europe. The company will expand collaborations with leading surgeons, renowned surgical centres, and strategic industry partners on both sides of the Atlantic to ensure a successful market launch and smooth integration into clinical practice. Additionally, the completion of UK clinical evaluation studies on colorectal and neurosurgery in the coming year will further enhance its evidence base.
See our official press release here.
Further selected stories associated with this announcement:
- Sifted: King’s College spinout raises £6.5m seed round to make surgery safer
- ZEISS Group: ZEISS Ventures participated in the funding round of Hypervision Surgical
- Life Extension Ventures: Our Investment in Hypervision Surgical & Trust in Venture Capital
- Computer Vision News: Hypervision Surgical - Precision Surgery
- The Mullings Group: Surgical AI venture Hypervision Surgical raises £6.5m Seed and adds CMR Surgical founder Martin Frost to the Board
- Imaging & Machine Vision Europe: AI-powered hyperspectral imaging to alleviate surgical complications
- UK Tech News: Hypervision Surgical scoops £6.5m for AI medical imaging
- EU-Startups: London-based Hypervision Surgical raises €7.5 million to redefine surgical imaging with AI and clinical edge computing
- Tech Funding News: How King’s medtech AI spinout Hypervision Surgical is powering the future of safer surgeries?
- King’s College London: King’s surgical AI spin-out Hypervision Surgical secures £6.5M seed investment